Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Ph+ CML Intolerant to Dasatinib
NCT02389920Phase 4Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Samsung Medical Center. Primary endpoint: The rate of improvement of Dasatinib-related adverse events at 3 months. Status: unknown.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02389920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389920.